MENINGVAX / POPULATION HEALTH INTELLIGENCE / 013
Global Meningitis
Epidemiology
Mapping the burden of meningitis across populations, geography, age groups, and time—from worldwide estimates to epidemic surveillance.
EXPLORE GLOBAL BURDEN ↗ REGIONAL PATTERNSPeople × Place × Time × Pathogen
01 / GLOBAL BURDEN
The global scale of meningitis
The GBD 2023 study quantifies meningitis mortality and incidence using multiple data sources and statistical models, providing a framework for global comparisons.
Source: Global Burden of Disease Study 2023. Values are rounded modeled estimates with uncertainty, not counts of laboratory-confirmed cases. Peer-reviewed study ↗
02 / EPIDEMIOLOGICAL DIMENSIONS
Four dimensions of disease burden
New infections
New meningitis cases over a specified period, often expressed per 100,000 people.
Deaths
Deaths attributable to meningitis, analyzed by age, pathogen, location, and year.
Long-term effects
Health loss from premature death and disability can be summarized using disability-adjusted life years.
Outbreak dynamics
Changes in case clusters, circulating strains, population immunity, and seasonal patterns.
03 / GEOGRAPHIC DISTRIBUTION
Disease burden is geographically unequal
Meningitis occurs worldwide, but pathogen distribution, outbreak risk, healthcare access, and vaccination coverage differ substantially across regions.
The African meningitis belt
Extending approximately from Senegal to Ethiopia, this region has historically experienced recurrent large-scale meningococcal epidemics, with pronounced seasonal patterns.
The introduction of meningococcal serogroup A conjugate vaccination transformed regional epidemiology, while other serogroups and pathogens remain important.
WHO AFRICAN REGION ↗North America & Europe
Routine immunization, clinical surveillance, and laboratory strain characterization inform prevention and outbreak response.
Asia & Pacific
Disease patterns are heterogeneous and reflect differences in pathogen circulation, vaccination programs, population structures, and diagnostic access.
Latin America & other regions
Country-level surveillance is essential for identifying locally important organisms and informing immunization policies.
04 / POPULATION RISK
Age and pathogen shape the risk
Etiological patterns differ by age and population. A global average cannot substitute for local laboratory surveillance.
05 / VACCINE-DRIVEN EPIDEMIOLOGY
Vaccination changes disease patterns
Conjugate vaccines can reduce disease caused by targeted organisms or serogroups. Their population impact is evaluated through long-term case-based and laboratory surveillance.
MenAfriVac impact
Introduction beginning in 2010 was associated with major reductions in serogroup A meningococcal disease and epidemic risk in vaccinated populations.
Conjugate vaccine programs
Pneumococcal vaccination reduces disease caused by covered serotypes; continued surveillance detects changes in circulating serotypes.
Hib disease prevention
Hib conjugate vaccines have substantially reduced invasive Hib disease where broadly implemented, illustrating the preventive value of routine immunization.
06 / PUBLIC HEALTH SURVEILLANCE
How epidemiological evidence is generated
High-quality monitoring integrates clinical reporting, laboratory testing, pathogen characterization, and population-level interpretation.
Case reporting
Identify suspected and confirmed disease.
Laboratory testing
Determine pathogens through suitable diagnostic methods.
Genomic analysis
Investigate strain relationships, serogroups, and resistance markers.
Public health action
Guide outbreak control, vaccination, and prevention policy.
07 / EPIDEMIOLOGY EXPLAINED
Frequently asked questions
How many people develop meningitis globally?
The GBD 2023 analysis estimated 2.54 million new cases worldwide in 2023. The number is a modeled estimate with uncertainty, not a complete count of reported diagnoses.
Where are meningitis epidemics most prominent?
The African meningitis belt has historically experienced major recurring meningococcal epidemics. Outbreaks can also occur elsewhere.
Which age groups are most affected?
Young children account for a substantial share of the global burden, while age-specific risk and causative organisms vary across populations.
Why is pathogen surveillance important after vaccination?
Surveillance measures vaccine impact and detects changes involving other circulating pathogens, meningococcal serogroups, or pneumococcal serotypes.
EVIDENCE LIBRARY
Scientific references
- GBD 2023 Meningitis Collaborators. Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet Neurology. 2026. PubMed ↗
- GBD 2019 Meningitis Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990–2019. The Lancet Neurology. 2023. PubMed ↗
- Trotter CL, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data. The Lancet Infectious Diseases. 2017. PubMed ↗
- MenAfriNet: A Network Supporting Case-Based Meningitis Surveillance and Vaccine Evaluation in the Meningitis Belt of Africa. Research article ↗
- World Health Organization. Meningitis: Fact Sheet. WHO ↗
- World Health Organization. Preventing and controlling meningitis outbreaks. WHO ↗
MENINGVAX / EXPLORE THE SCIENCE
Connect epidemiology with prevention
MeningVax Scientific Knowledge Platform · Evidence-based educational information. Epidemiological estimates depend on study methods, definitions, reporting coverage, and model uncertainty.